EXPORT CITATION

Chapter-094 Azilsartan for Hypertension Management in Cardiodiabetes

BOOK TITLE: Cardiodiabetes Update: A Textbook of Cardiology

Author
1. Wardhan Harsh
2. Aggarwal Nitin
ISBN
9789352703043
DOI
10.5005/jp/books/14130_95
Edition
1/e
Publishing Year
2018
Pages
6
Author Affiliations
1. Ram Monohar Lohia Hospital; Primus Super Speciality Hospital, New Delhi, India, Primus Superspecialty Hospital, New Delhi; RML Hospital and PGIMER, New Delhi, India, Primus Super Specialty Hospital; PGIMER and Dr RML Hospital, New Delhi, India, Rockland Group of Hospitals, New Delhi, India, Primus Super Speciality Hospital; RML Hospital and PGIMER, New Delhi, India, Primus Super Specialty Hospital, New Delhi, India, Primus Superspecialty Hospital; RML Hospital and PGIMER, New Delhi, India, Mahatma Gandhi Medical College and Hospital, Jaipur, Rajasthan, India
2. Saroj Hospital, Rohini, New Delhi, India, Shri Balaji Action Hospital, New Delhi, India, Action Balaji Hospital; Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India, Sri Balaji Action Medical Institute, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India, Rajiv Gandhi Cancer Institute and Research Center, Sri Balaji Action Hospital, New Delhi, India, Sri Balaji Action Medical Institute and Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India, Sri Balaji Action Medical Institute and Rajiv Gandhi Cancer Institute and Research Center, New Delhi, India
Chapter keywords
Azilsartan medoxomil, hypertension, cardiometabolic effect, ischemic heart disease, IHD, systolic blood pressure, SBP, angiotensin receptor blocker, ARB

Abstract

Azilsartan medoxomil is the newest approved ARB for the management of hypertension. It is a pro drug that is quickly hydrolyzed to the active moiety Azilsartan and reaches its peak plasma concentration between 1.5 hours and 3 hours following oral administration. It is an ARB with estimated bioavailability of 60% and elimination half-life of 11 hours. Azilsartan medoxomil emerges as a pleiotropic drug that may exert beneficial cardiometabolic effects beyond its antihypertensive properties. These favorable effects are more profound in comparison to other ARBs, probably due to higher affinity, tighter binding, and slower dissociation from AT1 receptors. This superiority was observed even when AZL-M was used in therapeutic doses in comparison to other ARBs that were administered above recommended clinical doses. Azilsartan medoxomil is a potent and well tolerated antihypertensive drug and there is indirect evidence of its efficacy and safety among diabetic patients. In comparison to other ARBs, the superior antihypertensive effect of AZL-M could be attributed to its unique binding properties.

Related Books

© 2019 Jaypee Brothers Medical Publishers (P) LTD.   |   All Rights Reserved